Digital health · Mental health
Meru Health
A 12 week virtual program pairing a licensed therapist with a heart rate variability biofeedback device. Ten years in, it has published more research than most of its peers, and one randomized trial against ordinary care that did not go its way.
A brother named Peter
Kristian Ranta’s older brother Peter died by suicide in 2005, after decades of depression the antidepressants he was prescribed did not fix. “For years, I wondered why he could not be treated effectively and how people like him could be helped in the future, before it’s too late,” he wrote later on the company blog.
In 2016 he started Meru Health with Riku Lindholm and Albert Nazander, two people he had known since school. What they built is not an app you download and use alone. A patient is matched with a licensed therapist, gets daily lessons drawn from cognitive behavioral therapy and mindfulness, joins an anonymous peer chat, and receives a wearable biofeedback device that measures heart rate variability and helps them train their breathing practices.
Then, after 12 weeks, it stops. The ending is the point. Ranta describes the company as selling “a programmatic offering, so kind of a therapy, which has a beginning and an end for most of our patients” rather than open ended sessions.
What the founders thought was broken
Two problems, in Ranta’s framing: people cannot get care, and the care they get often does not work. “So how can we make the care better so that people can actually heal, get better and stay better?” he asked Behavioral Health Business in 2021.
The first years went into research rather than growth. The company decided the evidence for digital therapy and for conventional psychiatry alike was thin, and reached a conclusion about its own category. As Meru put it to TechCrunch, “digital is great but without the human touch, it’s not going to get utilization.” Software alone loses people.
That thesis put a salaried clinician inside every subscription, and set up the question that follows every digital mental health company: better than what?
Three founders and a Helsinki clinic
Ranta is a three time healthcare entrepreneur with an IT background who had already run a diabetes care company. Lindholm became chief operating officer and Nazander led the technology. All three appear on the company’s SEC filings between 2019 and 2021.
The first version, called Ascend, ran out of an online clinic in Finland as an eight week course. Two pilot studies with 117 Finnish adults appeared in JMIR Formative Research in January 2019, reporting falling depression scores and noting that a controlled study design was still needed. Three months later the seed round closed, led by Freestyle Capital.
From Helsinki to the payers
Y Combinator took the company in Summer 2018. A $4.2 million seed followed in April 2019, an $8.1 million Series A in March 2020, and then the pandemic. Customers grew tenfold and revenue about 700 percent in 2020, Ranta told TechCrunch. September 2021 brought a $38 million Series B, $30 million of equity led by Industry Ventures plus $8 million of debt from J.P. Morgan, with about 170 staff.
“I can’t emphasize enough that we are in a mental health crisis right now,” Ranta said at the time.
The years since have been about getting paid. In March 2024 Meru put 100 percent of its fees at risk against outcome, access and engagement guarantees; fourteen months later Ranta said most payers could not administer it. On May 6, 2026 the company launched Meru Health Advanced, a 6 to 12 month program for treatment resistant patients adding a psychiatrist, a dietitian, a 30 to 50 biomarker lab panel and a Whoop wearable.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Randomized trial versus waitlist | NCT04738084, 2020 to 2021, 100 adults, 54 to the program and 46 to a waitlist. Published in the Journal of Affective Disorders, 2024. Effect size d = -0.8. A minimal clinically important difference was reached by 39.1 percent of the program group against 9.8 percent of the waitlist. | Public record |
| Randomized trial versus usual care | A 2021 Journal of Affective Disorders trial in a Finnish student health service randomized 124 patients to the program plus treatment as usual, or treatment as usual alone. Stated conclusion: “Most outcomes, including depression, did not significantly differ between MHP+TAU and TAU.” A post hoc subgroup on antidepressants did show an effect at 6 months. | Public record |
| Curcumin trial | NCT04744545, 60 adults, 2021. Both arms received the Meru Health Program; the randomization was curcumin or not, so it tests an additive, not the program. | Public record |
| Cancer feasibility study | NCT05588622, 22 adults with cancer, 2022 to 2023, single arm, with the Cancer Support Community and Eli Lilly. | Public record |
| NIMH funded primary care trial | NIMH awarded R44MH126836, $749,689, to Meru Health Medical, P.A. in April 2022 for a hybrid type 1 trial of depression screening and referral in primary care. The registered study, NCT05615662, is withdrawn with zero participants enrolled. | Public record |
| Published literature | 15 PubMed indexed papers name the program as of Sep 22, 2026, mostly retrospective cohort, observational or quasi experimental. A 2024 paper discloses that “Meru Health was the full-time employer of the authors at the time of the writing.” | Public record |
| The headline response rate | The May 2026 release says 67 percent of patients halve their depression symptoms in two to three months, against roughly 19 to 33 percent for SSRIs and 41 percent for psychotherapy. Those comparators come from other literature, not a head to head trial. The company’s own waitlist trial reported 39.1 percent. | Differs from the trials |
| Cost savings | An Accorded actuarial study compared 1,306 Meru engaged members with matched controls, 2021 to 2023: 55 percent fewer inpatient admissions, 31 percent fewer emergency visits, 23 percent lower prescription costs. No published version found. | Company-stated |
| Study count | The May 6, 2026 release says 14 peer reviewed studies. The company blog and Y Combinator post for the same launch say 17. | Company-stated |
| FDA status | No 510(k) or PMA record found. The program is clinician delivered, not marketed as a cleared device. | Not found |
Read plainly: this is one of the better documented companies in digital mental health, and the documentation is more careful than the marketing. Against a waitlist, four in ten patients reached a clinically important improvement where one in ten did untreated. Against care patients were already getting, the one randomized test found no difference on depression. The 55 to 67 percent response figures come from the company’s own cohorts; the SSRI and therapy numbers set beside them come from separate studies of separate populations. That is standard practice in this sector, and it is not the same as beating the alternative.
What to watch
- Whether the NIMH funded primary care trial is ever run. The award was $749,689 and the registered study was withdrawn with nobody enrolled.
- A randomized trial of Meru Health Advanced, or of the core program against active care rather than a waitlist.
- Payer coverage for Meru Health Advanced, which the company says it is still working to expand.
- Headcount. TechCrunch reported about 170 staff in 2021; the Y Combinator directory listed 55 in 2026.
- A new SEC Form D. The last one was filed on August 2, 2021.
In their words
“My family didn’t lose him because he gave up. We lost him because the system couldn’t help him get better.”
Kristian Ranta, founder and CEO, May 2026 launch release · Company release
“When standard treatment doesn’t work, the field has a name for you: treatment-resistant. I have come to believe that phrase is a confession.”
Kristian Ranta, company blog, May 2026 · Company
“We’re now showing with research that this approach has 3-5x better clinical results than the standard of care in the U.S., and a roughly 80% completion rate, which compares to 30% to 50% in traditional therapy because we engage people dramatically better.”
Kristian Ranta to TechCrunch, September 2021 · Independent
“Most outcomes, including depression, did not significantly differ between MHP+TAU and TAU.”
Conclusion of the randomized trial, Journal of Affective Disorders, 2021 · Public record
“There’s been more and more talk about the quality of care. Access is great, but then how do you make sure that access is to something that’s actually effective and good?”
Kristian Ranta, Behavioral Health Business podcast, June 2025 · Independent
“But generally for us, it has been a challenge working with payers in the market.”
Kristian Ranta, Behavioral Health Business podcast, June 2025 · Independent
“Every other field of medicine has moved toward measurement-based, personalized, whole-person treatment. Mental health has been the stubborn exception,”
Douglas Emch, MD, chief psychiatrist, May 2026 launch release · Company release
“Having met with scores of mental health startups over the last year, it was Meru’s full stack hybrid approach plus Kristian and his team’s dedication that spurred Freestyle’s decision to lead Meru’s seed.”
Josh Felser, founder, Freestyle Capital, April 2019 · Investor
Related companies
Sources
- Public recordClinicalTrials.gov NCT04738084, NCT04744545, NCT05588622, NCT05615662
- Public recordNIH RePORTER 1R44MH126836-01A1, NIMH
- Public recordTherapist-supported digital mental health intervention for depressive symptoms: A randomized clinical trial
- Public recordA therapist-guided smartphone app for major depression in young adults: A randomized clinical trial
- Public recordFeasibility of a Therapist-Supported Online Intervention for Depression
- Public recordForm D filings, Meru Health Holding Inc., CIK 0001774666
- IndependentMeru Health secures $38M in equity and debt for holistic online mental health platform
- IndependentDigital mental health startup Meru Health bags $38M
- IndependentMeru Health Eyes National Expansion
- InterviewCigna, Meru Health Tackle Behavioral Health’s Quality Conundrum
- CompanyMeru Health raises $4.2M in Funding
- CompanyMeru Health Launches Meru Health Advanced
- CompanyI lost my brother to traditional psychiatry
- CompanyMeru Health company and launch pages
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
